

**WEILL CORNELL MEDICAL COLLEGE CURRICULUM VITAE FORM**  
(REQUIRED FORMAT)

Version date:	January 7, 2019
---------------	-----------------

**A. GENERAL INFORMATION**

**Required Information:**

Name: First, Middle, Last	David A. Green
Office address:	56-45 Main St, Suite W-LL300, Flushing, NY 11355
Office telephone:	(718) 303-3720
Office fax:	(347) 394-5542
Beeper:	
Work Email:	<a href="mailto:Dag9025@nyp.org">Dag9025@nyp.org</a>
Citizenship:	United States

**B. EDUCATIONAL BACKGROUND**

1. **Academic Degree(s)**: B.A. and higher; institution name and location; dates attended; date of award. Expand the table as needed.

Degree (abbreviation)	Institution name and location	Dates attended	Year Awarded
B.S	Duke University, Durham, NC	8/94-5/98	1998
M.D.	Mount Sinai School of Medicine	7/2003-5/2005	2005
N/A	Thomas Jefferson School of Medicine	8/2001-6/2003	N/A

2. **Post-doctoral training (include residency/fellowships)**: In chronological order beginning with post-doctoral training positions; include full titles, ranks and inclusive dates held. Expand the tables as needed.

Title	Institution name and location	Dates held (mm/yy)
General Surgery Resident	St. Vincent's Catholic Medical Center	7/2005-6/2007
Urology Resident	New York Medical College	7/2007-

		6/2011
Urologic Oncology Fellow	Weill Cornell Medical College	8/2011-6/2013

3. Continuing Medical Education Courses/Certificates

Certificate or Course	Institution Name and Location	Dates attended
Victor F. Marshall Visiting Professorship	Weill Cornell, New York, NY	Fall/Winter: 2016, 2017, 2018
Society of Urologic Oncology Annual Meeting	San Antonio, TX	November 2016

C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure: Every physician appointed to the Hospital staff, except interns, and aliens in the US via non-immigrant visas, must have a New York State license or a temporary certificate in lieu of the license.

a. State	Number	Date of issue	Date of last registration
New York		7/18/2011	6/30/2017

2. Board Certification

Full Name of Board	Dates of Certification (mm/dd/yyyy) – Start and End Dates
American Board of Urology	2/28/15 - present

Malpractice Insurance

Do you have Malpractice Insurance?	Yes
Name of Provider: MCIC	

**D. PROFESSIONAL POSITIONS AND EMPLOYMENT**

1. Academic positions (teaching and research)

Title	Institution name and location	Dates held
Instructor	Weill Cornell Medical College	7/12-6/13
Assistant Professor of Clinical Urology	Weill Cornell Medical College	11/15-present

2. Hospital positions (e.g., attending physician)

Title	Institution name and location	Dates held
Staff Urologist	Hackensack UMC- Mountainside, Montclair, NJ	08/2013-10/2015
Staff Urologist	St. Barnabas Medical Center, Livingston, NJ	1/2014-10/2015
Urologic Surgeon	New York Presbyterian / Queens	11/2015 - present

**E. EMPLOYMENT STATUS (current or anticipated)**

Name of Employer(s): Weill Cornell Medical College
Employment Status (choose one, delete the others): Full-time salaried by Weill Cornell

**F. INSTITUTIONAL/HOSPITAL AFFILIATION**

1. Primary Hospital Affiliation:	New York Presbyterian / Queens
2. Other Hospital Affiliations:	New York Presbyterian / Weill Cornell Medical Center
3. Other Institutional Affiliations:	

**G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

CURRENT % EFFORT	(%)	Does the activity involve WCMC students/researchers? (Yes/No)
TEACHING	20	Yes
CLINICAL	70	Yes
ADMINISTRATIVE	5	No
RESEARCH	5	Yes
TOTAL	100%	

WCMC ANTICIPATED % EFFORT	(%)	Does the activity involve WCMC students/researchers? (Yes/No)
TEACHING	20	Yes
CLINICAL	70	Yes
ADMINISTRATIVE	5	No
RESEARCH	5	Yes
TOTAL	100%	

**INSTITUTIONAL RESPONSIBILITIES**

1. Teaching (e.g., specific teaching functions, courses taught, dates: For guidance refer to Teaching Metrics table. Report your teaching activities in the 4 areas of teaching shown below. To provide a more detailed teaching report, use the Teaching Activities Report template or Educator Portfolio template (strongly encouraged). Refer to it here as an attachment (e.g., see attached), and attach it to the CV.

<b><u>Didactic teaching:</u></b> (e.g., lectures, continuing medical education courses, grand rounds, professional development programs, seminars, tutorials)	
Core Curriculum lecture for General Surgery residents at NYP/Queens, "Genitourinary Trauma."	Dates: November 2017
<b><u>Mentorship:</u></b> (e.g., mentor for medical student, graduate student, resident, clinical or postdoctoral research fellow or junior faculty projects; service as graduate student thesis advisor or committee member)	
	Dates
<b><u>Clinical teaching:</u></b> (e.g., teaching in the clinic or hospital including bedside teaching, teaching in the operating room, preceptor in clinic)	
Daily interaction with Cornell Urology residents and fellows rotating to New York Presbyterian / Queens. Almost all surgeries I do involve working with a resident or a fellow. Daily rounds and bedside teaching also include residents and fellows on a regular basis.	Dates 11/2015-present

<b>Administrative teaching leadership role:</b> (e.g., residency or fellowship director, course or seminar director or co-director)	
	Dates

2. Clinical care (duties, dates): To document clinical activities use the table below or, to document extensive clinical activities use the [Clinical Portfolio template](#) (strongly encouraged). Refer to it here as an attachment and attach it to the CV.

Clinical Activity; Clinical Program Development	Dates
Full-time clinical schedule including office hours, ambulatory surgery, and major surgery.	November 2015 - present

3. Research (duties, dates): Summarize research activities in the table below. Provide key contributions, and annotate key grants and publications or use a [Statement of Key Contributions](#). Refer to it here and attach it to the CV.

Research Activity / Key Contributions	Dates
<i>Imaging &amp; Pathologic Correlates for Men At risk for Prostate Cancer.</i> Clinical lead for this IRB approved protocol based at NYP/Queens	1/2019 - present

4. Administrative Activities (duties, dates): Describe administrative activities in the table below. To document administrative activities more extensively use a supplemental statement, refer to it here and attach it to the CV.

Administrative Activity	Date
Director of Genitourinary Tumor Board, NYP/Queens	November 2015 – present
Regional Compliance Advisory Committee Member NYPQ Medical Group	November 2018 – present
GU DMT Prostate Group, NYP/Queens, Clinical Lead	August 2018 – present
Urology Triage and Peer Council, Committee member	August 2018 - present

## H. PROFESSIONAL MEMBERSHIPS

Include medical and scientific societies.

Member/Officer/Fellow/Role	Organization	Dates
Associate in Transit--Member	American Urological Association	08/07-present
Associate Member	Society of Urologic Oncology	10/13-present
Fellow	American College of Surgeons	10/18-present

## I. HONORS AND AWARDS

Name of award	Date awarded
2 <sup>nd</sup> Prize: Valentine Resident Essay Contest (Laboratory Investigation), New York, NY, 2011. Preventative Effect of Antioxidants on Oxidative Renal Cell Injury and the Role in Renal Crystal Formation.	3/2011
Physician Patient Communication: Most Improved HCAPS Score	2016-2017

## J. BIBLIOGRAPHY

Entries should follow standard journal format, listing all authors, complete titles and inclusive pagination. Please also provide a URL to each of your published works as found in a publicly available digital database such as PubMed or My Bibliography, which are maintained by the US National Library of Medicine.

Publications also may be annotated here (or in the Key Contributions Statement) to indicate the role of the candidate, where appropriate. This should be considered for co-first authorship, co-senior authorship, and in publications in which the candidate played an important role (leadership of a site, or methodology, etc.) that may not be apparent from the author order.

Number the entries and put your name in bold type. The listings must be organized in chronological order. Use the following categories:

### Articles in professional peer-reviewed journals

1) Al Hussein Al Awamlh B, Lee DJ, Nguyen DP, **Green DA**, Shariat SF, Scherr DS. Assessment of the quality-of-life and functional outcomes in patients undergoing cystectomy and urinary diversion for the management of radiation-induced refractory benign disease. Urology. 2015 Feb;85(2):394-400

2) Xylinas E, **Green DA**, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, Shariat SF, Scherr DS. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. Urology. 2013 Dec;82(6):1323-9.

3) Osborne JR, **Green DA**, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014 May;191(5):1439-45.

4) Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, **Green DA**, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, Shariat SF. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013 May;49(8):1889-97

5) Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, **Green DA**, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer. 2012 Nov 20;107(11):1826-32.

6) **Green DA**, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, Scherr DS, Shariat SF. Predictive tools for prostate cancer staging, treatment response and outcomes. Arch Esp Urol. 2012 Nov;65(9):787-807.

7) Xylinas E, Rink M, Novara G, **Green DA**, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF. Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy. Ann Surg Oncol. 2013 Mar;20(3):1027-34.

8) **Green DA**, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013 Apr;189(4):1214-21.

9) **Green DA**, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. BJU Int. 2013 Mar;111(3 Pt B):E78-84.

10) Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, **Green DA**, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int. 2013 Mar;111(3 Pt B):E30-6.

11) Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, **Green DA**, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS.

Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?

World J Urol. 2012 Dec;30(6):807-14.

12) Rink M, Hansen J, Cha EK, **Green DA**, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.

BJU Int. 2013 Jan;111(1):74-84.

13) **Green DA**, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int. 2013 Mar;111(3):404-11.

14) Rink M, Robinson BD, **Green DA**, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol. 2012 Aug;188(2):398-404.

15) **Green DA**, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, Shariat SF. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques.

BJU Int. 2012 Nov;110(10):1463-70.

16) Rink M, Cha EK, **Green D**, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep. 2012 Apr;13(2):122-35.

17) Rink M, Ehdaie B, Cha EK, **Green DA**, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol. 2012 Oct;62(4):677-84.

18) Bobby Alexander, M.D., Andrew I. Fishman, M.D., **David Green, M.D.**, Muhammad S. Choudhury, M.D., Sensusuke Konno, Ph.D. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells. Urologic Oncology: Seminars and Original Investigations. 2011 Jul 25. [Epub ahead of print]

19) Heiko Schöder, Ariela Noy, Mithat Gönen, Lijun Weng, **David Green**, Yusuf E. Erdi, Steven M. Larson, Henry W.D. Yeung. Intensity of



<sup>18</sup>Fluorodeoxyglucose Uptake in PET Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 23(21): 2005.

20) Montserrat Batlle, Ailan Lu, **David A. Green**, Yong Xue, and Jeanne P. Hirsch. Krh1p and Krh2p act downstream of the Gpa2p G-alpha subunit to negatively regulate haploid invasive growth. J. Cell Sci. 2003 116: 701-710.

## **Chapters**

**Green D** and Scherr D. Chapter: Costs of getting started and performing cystectomy. In "Robotic Surgery of the Bladder." Editors: Pruthi and Castle. Springer Publishing Company, 2012.

**Green D**, Grasso M. Complications of Laparoscopic and Robotic Radical Nephrectomy and Nephroureterectomy. In "Complications of Laparoscopic and Robotic Urologic Surgery." Editor: Ghavamian. New York: Springer Publishing Company; July 2010